1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. Cell Cycle | 细胞周期
  5. Antifolate

Calcium Levofolinate ( CL307782)

别名: Calcium Folinate; Calcium levofolinate; CL307782; CL 307782; CL-307782 左亚叶酸钙;左旋甲酰四氢叶酸钙;左旋亚叶本钙;左旋亚叶酸钙;左亚叶酸钙杂质;亚叶酸钙(左亚叶酸钙)
目录号: V2074 纯度: ≥98%
COA 产品数据 产品说明书 SDS
左亚叶酸钙（也称为亚叶酸钙；左亚叶酸钙；CL307782）是亚叶酸的钙盐和对映体活性形式，广泛用作癌症化疗的佐剂，例如癌症化疗。
Calcium Levofolinate ( CL307782) CAS号: 80433-71-2
产品类别: Antifolate
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
250mg
500mg
1g
2g
5g
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn

Other Forms of Calcium Levofolinate ( CL307782):

  • 亚叶酸二钠盐
  • 左亚叶酸
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

COA
MSDS
产品说明书
产品描述
左叶酸钙（也称为亚叶酸钙；左亚叶酸钙；CL307782）是亚叶酸的钙盐和对映体活性形式，广泛用作癌症化疗的佐剂，例如在骨肉瘤的高剂量甲氨蝶呤治疗后。左旋四氢叶酸用于治疗或预防接受甲氨蝶呤治疗骨癌的患者的甲氨蝶呤毒性作用。左旋四氢叶酸还用于与氟尿嘧啶 (5-FU) 联合化疗，以治疗已扩散到身体其他部位的结直肠癌。该药仅治疗结直肠癌的症状，并不治疗癌症本身。
生物活性&实验参考方法
体内研究 (In Vivo)
静脉注射（6、20 或 60 mg/kg/天）持续 4 周时，左旋四氢叶酸钙会增加 5-氟尿嘧啶的毒性[2]。
动物实验
Crj:CD(SD)BR rats (5 weeks)[2]
6, 20 or 60 mg/kg/day
i.v.; for 4 weeks (combined with 10 mg/kg/day 5-Fluorouracil)
毒性/毒理 (Toxicokinetics/TK)
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Leucovorin (folinic acid; 5-formyltetrahydrofolic acid) and its levo- isomer, levoleucovorin, are folic acid derivatives that are normal components of breastmilk. Because leucovorin and levoleucovorin are used as therapeutic agents with potentially toxic drugs such as fluorouracil or methotrexate, the LactMed record of the drug it is used with should be consulted.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Toxicity Data
Mouse(iv): LD50 732 mg/kg
参考文献

[1]. National Center for Biotechnology Information. PubChem Compound Summary for CID 135500522, Levoleucovorin calcium.

[2]. Effects of levofolinate calcium on subacute intravenous toxicity of 5-fluorouracil in rats. J Toxicol Sci. 1998 May;23 Suppl 1:11-29.

其他信息
Calcium folinate is a tetrahydrofolic acid.
Leucovorin Calcium is an active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs. Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)
Levoleucovorin Calcium is a levo isoform of leucovorin calcium with antineoplastic activity. Levoleucovorin is an active metabolite of folic acid, which does not require metabolism by dihydrofolate reductase. This agent counteracts the toxic effects of other folic acid derivative agents, rescuing the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
See also: Leucovorin (has active moiety); Leucovorin calcium; pyrimethamine (component of).
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C20H21N7O7.CA
分子量
511.5
精确质量
511.112
元素分析
C, 46.87; H, 4.33; Ca, 7.82; N, 19.13; O, 21.85
CAS号
80433-71-2
相关CAS号
80433-71-2 (Ca);163254-40-8 (sodium);68538-85-2;
PubChem CID
135403647
外观&性状
White to yellow solid powder
熔点
240-250ºC
LogP
0
tPSA
225.5
氢键供体(HBD)数目
5
氢键受体(HBA)数目
10
可旋转键数目(RBC)
7
重原子数目
35
分子复杂度/Complexity
900
定义原子立体中心数目
1
SMILES
C(N1[C@@H](CNC2C=CC(C(=O)N[C@H](C(=O)O)CCC(=O)O)=CC=2)CNC2NC(=NC(C1=2)=O)N)=O.[Ca]
InChi Key
KVUAALJSMIVURS-QNTKWALQSA-L
InChi Code
InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12-,13-;/m0./s1
化学名
calcium;(2S)-2-[[4-[[(6S)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate
别名
Calcium Folinate; Calcium levofolinate; CL307782; CL 307782; CL-307782
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮和光照。
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO: <1 mg/mL
Water: ~9 mg/mL (~17.6 mM)
Ethanol: <1 mg/mL
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.9550 mL 9.7752 mL 19.5503 mL
5 mM 0.3910 mL 1.9550 mL 3.9101 mL
10 mM 0.1955 mL 0.9775 mL 1.9550 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Treatment of Social and Language Deficits with Leucovorin for Young Children with Autism
CTID: NCT04060030
Phase: Phase 2    Status: Recruiting
Date: 2024-11-29
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
CTID: NCT02723994
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
Early Treatment of Language Impairment in Young Children with Autism Spectrum Disorder with Leucovorin Calcium
CTID: NCT04060017
Phase: Phase 2    Status: Recruiting
Date: 2024-11-29
Treatment of Acute Lymphoblastic Leukemia in Children
CTID: NCT00400946
Phase: Phase 3    Status: Completed
Date: 2024-11-27
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
CTID: NCT06703177
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2024-11-25
View More

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
CTID: NCT05564403
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
CTID: NCT06696768
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-11-20
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
CTID: NCT05836584
Phase: Phase 2    Status: Recruiting
Date: 2024-11-19
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
CTID: NCT04245865
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-14
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
CTID: NCT02890355
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
CTID: NCT00792948
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
CTID: NCT02112916
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
CTID: NCT02883049
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
CTID: NCT02101853
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
CTID: NCT00217737
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-12
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
CTID: NCT02912559
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-12
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
CTID: NCT04539808
Phase: Phase 2    Status: Recruiting
Date: 2024-11-06
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
CTID: NCT04248452
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
CTID: NCT04068103
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-04
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
CTID: NCT05677490
Phase: Phase 3    Status: Recruiting
Date: 2024-10-26
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
CTID: NCT04340141
Phase: Phase 3    Status: Recruiting
Date: 2024-10-26
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
CTID: NCT05610163
Phase: Phase 2    Status: Recruiting
Date: 2024-10-26
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
CTID: NCT00335816
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-22
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
CTID: NCT03959085
Phase: Phase 3    Status: Recruiting
Date: 2024-10-22
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
CTID: NCT02981628
Phase: Phase 2    Status: Recruiting
Date: 2024-10-22
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
CTID: NCT03914625
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
CTID: NCT00408005
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
CTID: NCT03007147
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-18
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
CTID: NCT06648525
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-18
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
CTID: NCT06247787
Phase: Phase 1    Status: Recruiting
Date: 2024-10-15
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
CTID: NCT04535401
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-10
Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing
CTID: NCT04723134
Phase: Phase 2    Status: Completed
Date: 2024-10-04
Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
CTID: NCT06078709
Phase: Phase 2    Status: Recruiting
Date: 2024-10-02
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
CTID: NCT00336024
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-01
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
CTID: NCT02003222
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-09-24
Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
CTID: NCT05688215
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-23
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies
CTID: NCT02419495
Phase: Phase 1    Status: Terminated
Date: 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
CTID: NCT06493760
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
CTID: NCT00492999
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
CTID: NCT04927780
Phase: Phase 3    Status: Recruiting
Date: 2024-08-28
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
CTID: NCT04205968
Phase: Phase 2    Status: Recruiting
Date: 2024-08-16
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
CTID: NCT03020030
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-08-15
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
CTID: NCT02828358
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-09
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
CTID: NCT03970252
PhaseEarly Phase 1    Status: Completed
Date: 2024-08-09
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
CTID: NCT06475326
Phase: Phase 2    Status: Recruiting
Date: 2024-08-09
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
CTID: NCT04141995
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-07
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
CTID: NCT05627635
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-08-06
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
CTID: NCT06531278
Phase: Phase 2    Status: Recruiting
Date: 2024-07-31
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
CTID: NCT05253846
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-07-25
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
CTID: NCT03488225
Phase: Phase 2    Status: Terminated
Date: 2024-07-16
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
CTID: NCT00557193
Phase: Phase 3    Status: Completed
Date: 2024-07-15
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
CTID: NCT00059930
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-07-03
Calcium Folinate Treatment of Spastic Paraplegia 56
CTID: NCT06478238
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-06-27
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
CTID: NCT05802056
Phase: Phase 1    Status: Recruiting
Date: 2024-06-21
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
CTID: NCT03337087
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-05-17
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
CTID: NCT04761614
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-05-16
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
CTID: NCT02366819
Phase: Phase 4    Status: Recruiting
Date: 2024-05-02
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
CTID: NCT00653068
Phase: Phase 3    Status: Completed
Date: 2024-04-23
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
CTID: NCT02730546
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-04-18
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
CTID: NCT03127124
Phase: Phase 1/Phase 2    Status: Withdrawn
Date: 2024-04-02
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
CTID: NCT00381680
Phase: Phase 3    Status: Completed
Date: 2024-03-26
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
CTID: NCT06313801
Phase: Phase 2    Status: Recruiting
Date: 2024-03-15
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
CTID: NCT04821284
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
CTID: NCT05148195
Phase: Phase 2    Status: Terminated
Date: 2024-03-13
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
CTID: NCT00544414
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-02-29
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
CTID: NCT04094688
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-02-26
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
CTID: NCT01190930
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-02-08
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
CTID: NCT04363801
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-01-22
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
CTID: NCT02553460
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-01-18
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
CTID: NCT02037048
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-01-08
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
CTID: NCT04233866
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-12-28
Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ
CTID: NCT04375605
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-12-26
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
CTID: NCT04164069
Phase: Phase 1    Status: Active, not recruiting
Date: 2023-12-12
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
CTID: NCT01897454
Phase: Phase 2    Status: Terminated
Date: 2023-12-05
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
CTID: NCT00873275
Phase: Phase 1    Status: Active, not recruiting
Date: 2023-11-30
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
CTID: NCT02047474
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-11-13
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
CTID: NCT00019760
Phase: Phase 2    Status: Completed
Date: 2023-10-31
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
CTID: NCT01307956
Phase: Phase 2    Status: Terminated
Date: 2023-10-26
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
CTID: NCT06094140
Phase: Phase 2    Status: Recruiting
Date: 2023-10-23
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
CTID: NCT01068327
Phase: Phase 1    Status: Completed
Date: 2023-10-10
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
CTID: NCT01959672
Phase: Phase 2    Status: Completed
Date: 2023-10-10
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
CTID: NCT00089024
Phase: Phase 2    Status: Completed
Date: 2023-09-29
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
CTID: NCT00039130
Phase: Phase 2    Status: Completed
Date: 2023-08-21
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
CTID: NCT00343408
Phase: Phase 1    Status: Completed
Date: 2023-08-04
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
CTID: NCT01835041
Phase: Phase 1    Status: Completed
Date: 2023-07-12
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
CTID: NCT00303628
Phase: Phase 3    Status: Terminated
Date: 2023-07-06
Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
CTID: NCT00003298
Phase: Phase 2    Status: Completed
Date: 2023-07-06
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
CTID: NCT00098787
Phase: Phase 2    Status: Completed
Date: 2023-07-05
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
CTID: NCT00002525
Phase: Phase 3    Status: Terminated
Date: 2023-06-28
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
CTID: NCT00002514
Phase: Phase 3    Status: Completed
Date: 2023-06-18
Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
CTID: NCT00004860
Phase: Phase 2    Status: Completed
Date: 2023-06-15
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
CTID: NCT00082797
Phase: Phase 2    Status: Completed
Date: 2023-06-15
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
CTID: NCT02333188
Phase: Phase 1    Status: Completed
Date: 2023-05-31
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
CTID: NCT02344810
Phase: Phase 1/Phase 2    Status: Withdrawn
Date: 2023-05-25
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
CTID: NCT02620865
Phase: Phase 1/Phase 2    Status: Completed
Date: 2023-05-15
Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients
CTID: NCT05846867
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2023-05-06
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
CTID: NCT01333033
Phase: Phase 2    Status: Completed
Date: 2023-04-13
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
CTID: NCT00005596
Phase: Phase 3    Status: Completed
Date: 2023-04-06
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
CTID: NCT00005585
Phase: Phase 3    Status: Completed
Date: 2023-04-06
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
CTID: NCT01256398
Phase: Phase 2    Status: Completed
Date: 2023-04-04
mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer
CTID: NCT05480280
Phase: Phase 2    Status: Recruiting
Date: 2023-02-28
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
CTID: NCT05640726
Phase: Phase 2    Status: Not yet recruiting
Date: 2022-12-07
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
CTID: NCT03518112
Phase: Phase 2    Status: Terminated
Date: 2022-11-04
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
CTID: NCT00467142
Phase: Phase 2    Status: Completed
Date: 2022-11-01
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
CTID: NCT01212822
Phase: Phase 2    Status: Completed
Date: 2022-09-07
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
CTID: NCT00936832
Phase: Phase 2    Status: Withdrawn
Date: 2022-08-30
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
CTID: NCT01535053
Phase: Phase 3    Status: Completed
Date: 2022-08-12
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
CTID: NCT01871571
Phase: Phase 2    Status: Unknown status
Date: 2022-08-09
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
CTID: NCT03110510
Phase: Phase 2    Status: Withdrawn
Date: 2022-06-15
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
CTID: NCT00006455
Phase: Phase 3    Status: Completed
Date: 2022-05-31
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
CTID: NCT00061945
Phase: Phase 1/Phase 2    Status: Completed
Date: 2022-05-03
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
CTID: NCT02293109
Phase: Phase 1    Status: Completed
Date: 2022-03-10
Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
CTID: NCT00001014
Phase: Phase 3    Status: Completed
Date: 2021-11-04
Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
CTID: NCT00001013
Phase: Phase 3    Status: Completed
Date: 2021-11-04
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
CTID: NCT00000973
Phase: Phase 1    Status: Completed
Date: 2021-11-04
A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP
CTID: NCT00000998
Phase: Phase 1    Status: Completed
Date: 2021-11-04
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
CTID: NCT00000703
Phase: N/A    Status: Completed
Date: 2021-11-03
Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
CTID: NCT00000730
Phase: Phase 3    Status: Terminated
Date: 2021-11-03
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
CTID: NCT00000658
Phase: Phase 3    Status: Completed
Date: 2021-11-03
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
CTID: NCT00000689
Phase: Phase 1    Status: Completed
Date: 2021-11-02
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
CTID: NCT00000643
Phase: Phase 2    Status: Completed
Date: 2021-11-02
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
CTID: NCT01412879
Phase: Phase 2    Status: Completed
Date: 2021-10-29
An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies
CTID: NCT00000714
Phase: Phase 3    Status: Completed
Date: 2021-10-29
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
CTID: NCT00000794
Phase: Phase 2    Status: Completed
Date: 2021-10-28
The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer
CTID: NCT00000723
Phase: N/A    Status: Terminated
Date: 2021-10-28
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
CTID: NCT02015819
Phase: Phase 1    Status: Completed
Date: 2021-10-20
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
CTID: NCT00070213
Phase: Phase 3    Status: Completed
Date: 2021-09-27
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
CTID: NCT00640081
Phase: Phase 2    Status: Completed
Date: 2021-09-22
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
CTID: NCT01666730
Phase: Phase 2    Status: Completed
Date: 2021-08-10
Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer
CTID: NCT02270606
Phase: Phase 1    Status: Completed
Date: 2021-07-20
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
CTID: NCT00103285
Phase: Phase 3    Status: Completed
Date: 2021-06-14
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
CTID: NCT00075725
Phase: Phase 3    Status: Completed
Date: 2021-04-27
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
CTID: NCT01280643
Phase: N/A    Status: Terminated
Date: 2021-03-15
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
CTID: NCT00112658
PhasePhlse if(down_display === 'none' || down_display === '') { icon_angle_up.style.display = 'none'; icon_angle_down.style.disp

相关产品
联系我们
电话: 020-31522723 QQ： 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member